Sphere Fluidics’ Cyto-Mine is an automated cell line platform that is designed to enable screening of up to 40 million cells over the course of several hours.
Sphere Fluidics’ Cyto-Mine is an automated cell line platform that integrates single cell screening, sorting, dispensing, imaging, and clone verification into one solution. Intended for use in various research areas, including antibody discovery, cell-line development, cell engineering, and synthetic biology, the device uses a unique microfluidic picodroplet technology that is designed to enable screening of up to 40 million cells over the course of several hours.
Recent software updates to the Cyto-Mine have been made to ensure compliance with current good manufacturing practice regulations. These updates include 21 CFR Part 11, FDA’s regulation for electronic documentation and electronic signatures, and a full installation qualification/operation qualification package, which is intended to support quick and easy equipment qualification.